GlutDigestP: GlutDigest - Pilot Study

Sponsor
Deerland Enzymes (Industry)
Overall Status
Completed
CT.gov ID
NCT04489836
Collaborator
Teagasc (Industry), Atlantia Food Clinical Trials (Industry)
2
1
2
19
3.2

Study Details

Study Description

Brief Summary

This is a pilot, feasibility study to evaluate, test and optimize sample analysis procedures and protocols before the full-scale, crossover study is conducted.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Glutalytic®
  • Dietary Supplement: DE111®
  • Other: Meal A
N/A

Detailed Description

Two important factors can influence the proportions of gluten and starch that resist digestion: (1) enzyme availability and specificity and (2) the structural properties of the food. A complete evaluation of gluten digestion and of the impact of dietary supplements is difficult to conduct because it is not easy to obtain samples of digestive chime. The analysis of the ileal effluent of healthy ileostomy patients constitutes a non-invasive alternative to intubation techniques for the study of nutrient digestion and of the fate of probiotics in the small intestine.

The main aim of this study is to test and optimize sample analysis protocols before conducting the full-scale, crossover study which will aim at evaluating the impact of two dietary supplements (Glutalytic® and DE111®) and of oatmeal properties on the digestion of gluten and starch and on the glycemic response.

Study Design

Study Type:
Interventional
Actual Enrollment :
2 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
GlutDigest - Enzymes-assisted Gluten Digestion (Pilot Study)
Actual Study Start Date :
Aug 31, 2020
Actual Primary Completion Date :
Sep 19, 2020
Actual Study Completion Date :
Sep 19, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Meal A + Glutalytic®

350 mg Glutalytic® capsule, taken by mouth, once, with Meal A

Dietary Supplement: Glutalytic®
Glutalytic® capsule

Other: Meal A
Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Experimental: Meal A + DE111®

350 mg DE111® capsule, taken by mouth, once, with Meal A

Dietary Supplement: DE111®
DE111® capsule

Other: Meal A
Oatmeal porridge - serving of oat porridge (cooked) containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Outcome Measures

Primary Outcome Measures

  1. Undigested wheat protein after each treatment [9-hour period after the test meal]

    Difference between the mean concentration of undigested wheat protein in ileal effluent samples.

Secondary Outcome Measures

  1. Vegetative DE111 cells [9-hour period after the test meal]

    Mean concentration of DE111® cells recovered in the ileal effluent samples.

  2. Glycemic response [At baseline, and at different time-points in the 9-hour period after consumption of the test meal.]

    Difference between the mean area under the glucose concentration (measured in the interstitial fluid) curves following each treatment.

  3. Undigested starch [9-hour period after the test meal]

    Difference between the mean concentration of undigested starch in ileal effluent samples.

  4. Undigested food particles [9-hour period after the test meal]

    Pictures of undigested foods particles and microscopy will be combined for a combined assessment of macro- and micro- structural characteristics of the food particles recovered in ileal effluent samples.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subject has given written informed consent

  • Subject has an ileostomy stable for at least 3 months post-operative and shows normal stoma functions

  • Subject is otherwise healthy

  • Subject is available to participate in the study sessions on the proposed dates

Exclusion Criteria:
  • Subject has coeliac disease or allergy to wheat products and/or any other ingredients in the test meal and standard meals

  • Case of obstruction of the stoma in the past 3 months

  • Body mass index < 18 kg/m2 or > 30 kg/m2.

  • Diagnosed mouth, throat or active gastrointestinal pathology (other than ileostomy) that may affect normal ingestion and digestion of food.

  • History of pancreatic disease

  • Subject is immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy within the last year)

  • Subject has Type 1 or Type 2 diabetes mellitus.

  • Subject has a history of bariatric surgery.

  • Subject has a history of drug and/or alcohol abuse at the time of enrolment

  • Subject is currently participating in another study, or plans to participate in another study during the study period

  • Women of child-bearing potential who do not use an acceptable method of contraception

  • Pregnant or nursing (lactating) women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Atlantia Food Clinical Trials Cork Ireland

Sponsors and Collaborators

  • Deerland Enzymes
  • Teagasc
  • Atlantia Food Clinical Trials

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Deerland Enzymes
ClinicalTrials.gov Identifier:
NCT04489836
Other Study ID Numbers:
  • Project 0470-Pilot study
First Posted:
Jul 28, 2020
Last Update Posted:
Oct 23, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Deerland Enzymes

Study Results

No Results Posted as of Oct 23, 2020